Reference : Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagno...
Scientific journals : Article
Human health sciences : Hematology
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Amadori, Sergio []
Suciu, Stefan []
Selleslag, Dominik []
Aversa, Franco []
Gaidano, Gianluca []
Musso, Maurizio []
Annino, Luciana []
Venditti, Adriano []
Voso, Maria Teresa []
Mazzone, Carla []
Magro, Domenico []
De Fabritiis, Paolo []
Muus, Petra []
Alimena, Giuliana []
Mancini, Marco []
Hagemeijer, Anne []
Paolini, Francesca []
Vignetti, Marco []
Fazi, Paola []
Meert, Liv []
Ramadan, Safaa Mahmoud []
Willemze, Roel []
de Witte, Theo []
Baron, Frédéric mailto [Université de Liège > > GIGA-R : Hématologie >]
Journal of Clinical Oncology
American Society of Clinical Oncology
Yes (verified by ORBi)
[en] Purpose
To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid leukemia unsuitable for intensive chemotherapy.
Patients and Methods
In this trial, patients at least 61 years old were centrally randomized (1:1) to receive either a single induction course of GO (6 mg/m2 on day 1 and 3 mg/m2 on day 8) or BSC. Patients who did not progress after GO induction could receive up to eight monthly infusions of the immunoconjugate at 2 mg/m2. Randomization was stratified by age, WHO performance score, CD33 expression status, and center. The primary end point was overall survival (OS) by intention-to-treat analysis.
A total of 237 patients were randomly assigned (118 to GO and 119 to BSC). The median OS was 4.9 months (95% CI, 4.2 to 6.8 months) in the GO group and 3.6 months (95% CI, 2.6 to 4.2 months) in the BSC group (hazard ratio, 0.69; 95% CI, 0.53 to 0.90; P = .005); the 1-year OS rate was 24.3% with GO and 9.7% with BSC. The OS benefit with GO was consistent across most subgroups, and was especially apparent in patients with high CD33 expression status, in those with favorable/intermediate cytogenetic risk profile, and in women. Overall, complete remission (CR [complete remission] + CRi [CR with incomplete recovery of peripheral blood counts]) occurred in 30 of 111 (27%) GO recipients. The rates of serious adverse events (AEs) were similar in the two groups, and no excess mortality from AEs was observed with GO.
First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy. No unexpected AEs were identified and toxicity was manageable.

File(s) associated to this reference

Fulltext file(s):

Open access
2016_Amadori_GO_AML19_JCO.pdfPublisher postprint866.71 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.